Physician
Hematology
Dr. Muhammad S. Shurafa, MD
|
|
Give Review
Muhammad S. Shurafa, MD is an expert in the field of Hematology. He went to Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. He over the years received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Muhammad S. Shurafa is also a published doctor. He has 27 publication published. The most recent publication is: Mutation analysis of the HFE gene associated with hereditary hemochromatosis in African Americans. He accepts all Medicare patients.
Publications
- Chronic abdominal pain caused by heterotopic ossification with functioning bone marrow: a case report and review of the literature.
- Mutation analysis of the HFE gene Associated with hereditary hemochromatosis in African Americans.
- Factor VII G331D: a variant molecule involving replacement of a residue in the substrate-binding region of the catalytic domain.
- Carboplatin infusion in relapsed and refractory Acute myeloid leukemia--a Southwest Oncology Group trial.
- Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma.
- Impaired antibody responses to a pneumococcal polysaccharide vaccine in patients with non-Hodgkin's Lymphoma in remission.
- U-variant blood in sickle Cell patients.
- Trisomy 15, sex chromosome loss, and Hematological malignancy.
- Clinical significance of Y chromosome loss in Hematologic disease.
- Significance of p53 mutations in patients with chronic lymphocytic Leukemia: a sequential study of 30 patients.
- Laparoscopic excision of accessory spleen.
- Prostaglandin F2-alpha bladder irrigation for control of intractable cyclophosphamide-induced hemorrhagic cystitis.
- Management of neck bleeding in patients With inhibitors to factor VIII.
- Management of dental extractions in two Hemophilia A patients with factor VIII inhibitor.
- Benefit of cyclosporine modulation of drug resistance in patients with poor-risk Acute myeloid leukemia: a Southwest Oncology Group study.
- Prognostic factors and response to fludarabine therapy in patients With Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Gr...
- Clinical and quality of life outcomes of laparoscopic and open splenectomy for haematological Diseases.
- A phase I study of induction chemotherapy for older patients with newly diagnosed Acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC...
- Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic Leukemia.
- Waldenström's Macroglobulinemia in young African-American adults.
- Long survival in sickle cell Anemia.
- Thalidomide for the treatment of bleeding angiodysplasias.
- Surgical indications in idiopathic splenomegaly.
- A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias.
- Treatment of cyclophosphamide-induced intractable hemorrhagic cystitis.
- PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an Acute myeloid leukemia patient with a t(X;21)(p22;q22).
Schools
American University of Beirut Faculty of Medicine
American University Hospital
Cmdnj Rutgers Affil Hosps
Wayne State University
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Health Alliance
- Preferred PPO
- Harvard Pilgrim Health Care PPO
- HealthPartners
- Choice Care PPO
- McLaren Health Plan
- Medicaid
- Medicare MCR
- Molina
- Priority PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Wayne State University School of Medicine -
UMDNJ-Robert Wood Johnson Medical School -
American University of Beirut Faculty of Medicine
Drug Facts
| NPI NUMBER | 1184638041 | |
| NPPES Provider LastName | SHURAFA | |
| NPPES Provider FirstName | MUHAMMAD | |
| NPPES Provider ZIPCode | 482362857 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 645.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 20.0 | |
| Percent Opioid Claims | 3.1 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184638041 |
| Last Name Of The Provider | SHURAFA |
| First Name Of The Provider | MUHAMMAD |
| View All |
Similar Doctors
|
|
Dr. Fikry F. Ibrahim, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ayad M. Al-Katib, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zyad Kafri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew T. Schubeck, MD |
|
|
Dr. Michael J. McKenzie, DO |
|
|
Dr. Jing C. Ye, MD |
|
|
Dr. Muhammad I. Zulfiqar, MD |